Charlotte Robinson

DocwireNews

Maximal dosing of renin-angiotensin-aldosterone inhibitors (RAASi) for patients with heart failure and reduced ejection fraction (HFrEF) can reduce hospitalization and mortality. However, when chronic kidney disease (CKD) is also present, the risk of hyperkalemia introduces challenges to optimal RAASi dosing.Debasish&nbsp;Banerjee and colleagues studied the role the potassium binder sodium zirconium cyclosilicate (SZC) might play in maximizing RAASi without resultant hyperkalemia in patients with HFrEF and moderate to severe CKD (estimated glomerular filtration rate [eGFR] &lt;60 mL/min/1.73 m2).Their double-blind, placebo-controlled trial included 112 participants, randomized to SZC (n=53) or placebo (n=59) with two weekly interventions. Study outcomes included the percentage of patients in each arm reaching the target dose of RAASi without experiencing hyperkalemia (serum potassium &gt;5.5 mmol/L) or severe hyperkalemia (serum potassium &gt;6.0 mmol/L) and the number of patients developing hyperkalemia or severe hyperkalemia.The mean (&plusmn; SD) participant age was 74&plusmn;11 years, 73% were male, and 67% were White. In addition, 54% had diabetes, 11% were current smokers, 62% had a history of ischemic heart disease, and 35% had CKD stages 4-5. Baseline eGFR was 35&plusmn;12 mL/min/1.73 m2. Baseline characteristics were well matched between the two groups. Sacubitril/valsartan and eplerenone were the most common types of RAASi used.On average, serum potassium levels increased in both the SZC and placebo groups by 0.03 mmol/L (95% CI, 0.005-0.05; P=.015) biweekly during the follow-up period. However, average serum potassium throughout the study period was 0.32 mmol/L (95% CI, 0.23-0.40; P&lt;.001) lower in the SZC group than in the placebo group, accounting for the follow-up period.Forty-three (39%) participants achieved the maximal RAASi dose without hyperkalemia: 21 (40%) in the SZC group and 22 (38%) in the placebo group. There was no statistical difference between the two groups (P=.792). Nineteen of 32 (59%) participants in the SZC group reached half the maximum dose of RAASi from less than half the dose compared with 10 of 23 (43%) patients in the placebo group, without hyperkalemia. There was no statistical difference between the two groups (P=.283).Forty-one patients developed hyperkalemia (serum potassium &gt;5.5 mmol/L) over the study period: 27 (47%) in the placebo group and 14 (27%) in the SZC group (P=.040). Four patients in the SZC group and 12 patients in the placebo group developed severe hyperkalemia (serum potassium &gt;6.0 mmol/L; P=.059).The authors concluded that, &ldquo;In this study of rapid RAASi maximization, hyperkalemia (&gt;5.5 mmol/L) was more common in patients on placebo compared to SZC; however, there was no statistically significant difference in proportion of patients who reached target dose of RAASi in CKD patients with HFrEF.&rdquo;Source: Banerjee D,&nbsp;Ster IC,&nbsp; Ali M, et al. Maximisation of renin-angiotensin-aldosterone inhibitors in heart failure patients with CKD using potassium binder; preliminary analysis of a randomised double-blind placebo-controlled trial. Abstract #WCN25-4625. Presented at the World Congress of Nephrology; February 6-9, 2025; New Delhi, India. Funding was provided by an externally sponsored research program of AstraZeneca.&nbsp;

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

SZC for RAASi Maximization Among Patients With CKD, HFrEF

WCN 2025

What role can sodium zirconium cyclosilicate (SZC) play in RAASi maximation without resultant hyperkalemia in patients with HFrEF and chronic kidney disease (CKD)?

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe